Rejuvenating the brain. Extending human healthspan.
The brain is the rate-limiter of a long, lucid life. L3 Labs engineers non-invasive medicines that restore the aging brain to a younger, sharper state, built on a delivery platform that turns the nose into a factory for the brain's own regenerative proteins.
Longevity is won or lost in the brain.
We can already extend how long the body lasts. But a longer life is only worth living if the mind comes with it. The aging brain loses synapses, plasticity, and the capacity to renew itself, and that decline sets the ceiling on healthspan. L3 Labs exists to lift that ceiling.
Restore, don't just slow
Existing neurodegeneration drugs slow decline at best. Our approach rebuilds the synaptic and regenerative machinery that aging strips away, a neurorestorative mechanism, not a brake.
The nose makes the medicine
Rather than injecting a fragile protein drug, we deliver instructions that program cells in the nasal lining to produce regenerative proteins, which then travel the nose-to-brain route to the brain.
A healthier mind, for longer
Our north star is healthspan: keeping memory, learning, and cognitive resilience intact deep into late life, and one day, pushing those limits beyond the normal human range.
Born from longevity research
The premise behind L3 Labs comes from our founders’ own lab: research showing that targeting the brain can extend lifespan. That finding, that brain health helps set the pace of aging, is why we built these medicines. The lead program applies that principle through a new target and a non-invasive route.
A drug factory at the nose-brain interface.
For decades, the brain's most powerful regenerative proteins couldn't be used as medicines, they can't cross the blood-brain barrier and are destroyed in minutes. Our intranasal mRNA-lipid-nanoparticle platform sidesteps both problems at once.
Self-administered nose drops
No injections, no infusions, no surgery, a once- or twice-daily intranasal dose at home.
Cells become the factory
mRNA programs cells in the nasal lining to transiently produce and secrete a therapeutic protein on site.
Direct to the brain
The protein travels the nose-to-brain axis, reaching the brain without entering the bloodstream or the rest of the body.
One platform, many cargoes
Swap the mRNA, change the medicine. The same delivery system carries a growing pipeline of regenerative cargoes.
What the lead program has already shown in animal models:
Two assets. One mission: a younger brain.
Our lead medicine rejuvenates the healthy aged brain and is moving into formal safety studies. A second, purpose-designed asset is in active efficacy testing. Both ride the same validated delivery platform.
Brain rejuvenation
Brain rejuvenation
Bars show the furthest stage each program has reached. Both run on one intranasal mRNA-LNP delivery platform. Preclinical data are not yet peer reviewed; no L3 Labs product has been tested in humans.
The regulatory on-ramp: MCI & early Alzheimer's
Longevity is the mission; the clinic is the path. We enter humans through mild cognitive impairment and early Alzheimer's disease, indications with clear, accelerable FDA pathways and validated, mechanism-matched biomarker endpoints. A positive first-in-human readout de-risks every downstream use of the platform, including healthy-brain aging. Read our Alzheimer's & MCI strategy →
Grounded in rigorous preclinical science.
The founding science originates from the Dr. John and Anne Chong Laboratory for Functional Genomics at the Charles Perkins Centre, University of Sydney, one of Australia's premier translational research centres.
All efficacy and biodistribution figures are from preclinical (cell and mouse) studies; the founding work (Bergamasco, Clark, Loo et al., University of Sydney) is available as a preprint and has not yet been peer reviewed. Nose-to-brain delivery of mRNA-LNPs that bypasses the blood-brain barrier has separately been reported in the peer-reviewed literature (Yu et al., ACS Nano, 2026). No L3 Labs product has been tested in or approved for use in humans. Forward-looking statements are subject to clinical, regulatory and commercial risk.
See the full evidence →The first credible shot at rejuvenating the human brain.
mRNA is proven in humans
Billions of mRNA-LNP doses have established the safety and manufacturability of the underlying technology. We point that proven modality at the brain.
A clinically de-risked target
Delivering neurotrophic factors into the human brain is not unproven biology. Viral gene-therapy programs run by others have shown this class of factors can be delivered to the patient brain safely and remain biologically active. L3 Labs pursues that validated target through a non-invasive, non-viral route.
A delivery problem, finally solved
The reason neurotrophic medicines failed for decades was delivery, not biology. Our nose-to-brain route removes that single point of failure.
Regulators are leaning in
The FDA now supports accelerated, biomarker-based pathways in the early-Alzheimer's continuum, shortening the road from data to patients.
Healthspan is the defining market
Extending healthy years, especially cognitive ones, is the most valuable unmet need in medicine, and the fastest-growing focus of long-horizon capital.
Scientist-founders, commercially trained.
Prof. Greg Neely
Functional genomics and neuroscience, Charles Perkins Centre, University of Sydney.
Dr. Adam Cole
Translational development and platform strategy.
Dr. Julius Juarez
Biotech commercialisation and corporate strategy.
Dr. Maria Bergamasco
Behavioural neuroscience and cognition; co-inventor of L04 and L05.
The founding team completed the CSIRO ON Accelerate commercialisation program (2025) and is participating in the Cicada Innovations STRIDE program (2026), with mentorship focused on biotech commercial and strategic development.
More about the company →
Help us push the limits of the human brain.
We're building the company that makes brain rejuvenation a clinical reality, and partnering with the people and institutions who want to extend not just lifespan, but the years we stay fully ourselves.
Start a conversation